Identifying Effective Treatment for Veterans Unwilling to Quit Smoking

Sponsor
VA Office of Research and Development (U.S. Fed)
Overall Status
Recruiting
CT.gov ID
NCT04061720
Collaborator
University of Wisconsin, Madison (Other)
500
1
2
58.6
8.5

Study Details

Study Description

Brief Summary

This project will generate knowledge about the effectiveness of Enhanced Chronic Care, an intervention designed to enhance treatment use and smoking abstinence in Veterans who are initially unwilling to quit. Enhanced Chronic Care provides ongoing motivational interventions and interpersonal support designed to promote readiness to quit smoking. Enhanced Chronic Care will be compared with Standard Care (brief advice to quit once per year) on criteria that are of great clinical and public health importance: use of cessation treatment and smoking abstinence. It is expected that Enhanced Chronic Care will increase treatment use and smoking abstinence relative to Standard Care.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Enhanced Chronic Care
  • Behavioral: Standard Care
N/A

Detailed Description

This project will generate knowledge about the effectiveness of Enhanced Chronic Care, an intervention designed to enhance treatment use and smoking abstinence in Veterans who are initially unwilling to quit. Enhanced Chronic Care provides ongoing motivational interventions and interpersonal support designed to promote readiness to quit smoking. Enhanced Chronic Care will be compared with Standard Care (brief advice to quit once per year) on criteria that are of great clinical and public health importance: smoking treatment reach (use of cessation treatment) and abstinence. It is expected that Enhanced Chronic Care will increase treatment use and smoking abstinence relative to Standard Care.

The investigators will evaluate these interventions using a 2-arm randomized controlled trial. Veterans who smoke daily, but who are not willing to enter smoking cessation treatment, will be eligible to participate, with no obligation to quit smoking. Participants (N=500) will be randomized to one of the following treatments: 1) Enhanced Chronic Care (n=250) or 2) Standard Care (n=250). These intervention conditions will last 2 years to permit analysis of their cumulative impact on abstinence and treatment use

Study Design

Study Type:
Interventional
Anticipated Enrollment :
500 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Treatment
Official Title:
Identifying Effective Treatment for Veterans Unwilling to Quit Smoking
Actual Study Start Date :
Nov 12, 2019
Anticipated Primary Completion Date :
Sep 30, 2024
Anticipated Study Completion Date :
Sep 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Enhanced Chronic Care

Enhanced Chronic Care provides ongoing, phone-based motivational interventions and interpersonal support to promote readiness to quit, with facilitated access to evidence-based smoking treatment.

Behavioral: Enhanced Chronic Care
Enhanced Chronic Care involves four chronic care calls per year. Enhanced Chronic Care is designed to help participants explore their goals and concerns with regard to smoking, engage in a nondirective, supportive, motivational interventions, and provide information about evidence-based smoking treatment available to them and ways to initiate treatment (i.e., warm hand-off from a clinical provider).

Active Comparator: Standard Care

Standard Care provides phone-based brief advice to quit once per year.

Behavioral: Standard Care
Standard Care involves one call per year. During the Standard Care call, participants will be encouraged to quit smoking, reminded of the cessation treatment available to them, and provided with a number to call should they become interested in treatment.

Outcome Measures

Primary Outcome Measures

  1. 7-Day Point-Prevalence Abstinence [2 years]

    Participants who self-report no smoking for the past 7 days at the assessment endpoint (2-year follow-up) will be considered to meet criteria for 7-Day Point-Prevalence Abstinence. Participants who report any smoking in the past 7 days (at the 2 year follow-up) will be considered to be relapsed (smoking).

Secondary Outcome Measures

  1. Initiating at least 1 cessation treatment call [2 years]

    Cessation treatment use will be defined as making at least one treatment contact (initiating at least 1 cessation treatment call with reach coded as a binary outcome: use vs. no use).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Not willing to set a quit date in the next 30 days

  • Report smoking an average of 4 or more cigarettes daily for at least six months

  • Read, write, and speak English

  • Be medically eligible to use nicotine replacement therapy

  • If female, use an approved method of birth control if they use nicotine replacement therapy

  • Agree to participate in the study

  • Be at least 18 years old

  • Be a Veteran

Exclusion Criteria:
  • Unable to give informed, voluntary consent to participate

  • Current use of any pharmacotherapy for smoking cessation not provided by the researchers during tobacco treatment

  • Use of non-cigarette tobacco products as a primary form of tobacco use

  • Incarceration

Contacts and Locations

Locations

Site City State Country Postal Code
1 William S. Middleton Memorial Veterans Hospital, Madison, WI Madison Wisconsin United States 53705

Sponsors and Collaborators

  • VA Office of Research and Development
  • University of Wisconsin, Madison

Investigators

  • Principal Investigator: Jessica Megan Cook, PhD, William S. Middleton Memorial Veterans Hospital, Madison, WI

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT04061720
Other Study ID Numbers:
  • NURA-009-18F
First Posted:
Aug 20, 2019
Last Update Posted:
Jan 20, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by VA Office of Research and Development
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 20, 2022